Danaher Corporation $DHR Shares Bought by Blue Trust Inc.

Blue Trust Inc. boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 1.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 10,937 shares of the conglomerate’s stock after purchasing an additional 106 shares during the period. Blue Trust Inc.’s holdings in Danaher were worth $2,161,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MGO One Seven LLC grew its position in Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock worth $5,145,000 after purchasing an additional 20,813 shares during the period. Chicago Capital LLC grew its position in Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after purchasing an additional 1,391 shares during the period. UniSuper Management Pty Ltd grew its position in shares of Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after acquiring an additional 2,667 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new stake in shares of Danaher during the 1st quarter valued at about $539,000. Finally, Horizon Financial Services LLC grew its position in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after acquiring an additional 8,160 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 1.0%

Shares of Danaher stock opened at $202.53 on Friday. The firm has a market capitalization of $145.02 billion, a PE ratio of 43.09, a P/E/G ratio of 2.91 and a beta of 0.77. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The firm’s 50-day moving average price is $200.66 and its 200 day moving average price is $197.25. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the company posted $1.72 EPS. Danaher’s quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on DHR shares. Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research report on Wednesday. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a research report on Friday, July 11th. Wells Fargo & Company dropped their target price on Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 23rd. Finally, Rothschild Redb cut Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $244.60.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.